(Q40041623)

English

Interactions of myeloma cells with osteoclasts promote tumour expansion and bone degradation through activation of a complex signalling network and upregulation of cathepsin K, matrix metalloproteinases (MMPs) and urokinase plasminogen activator (uP

scientific article published on 7 November 2007

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

16 September 2017

Interactions of myeloma cells with osteoclasts promote tumour expansion and bone degradation through activation of a complex signalling network and upregulation of cathepsin K, matrix metalloproteinases (MMPs) and urokinase plasminogen activator (uP (English)

1 reference

Europe PubMed Central

16 September 2017

1 reference

based on heuristic

inferred from title

author name string

Monica Hecht

1

1 reference

Europe PubMed Central

16 September 2017

Ivana von Metzler

2

1 reference

Europe PubMed Central

16 September 2017

Katja Sack

3

1 reference

Europe PubMed Central

16 September 2017

Martin Kaiser

4

1 reference

Europe PubMed Central

16 September 2017

Orhan Sezer

5

1 reference

Europe PubMed Central

16 September 2017

language of work or name

0 references

publication date

7 November 2007

1 reference

Europe PubMed Central

16 September 2017

Experimental Cell Research

1 reference

Europe PubMed Central

16 September 2017

314

1 reference

Europe PubMed Central

16 September 2017

1082-1093

1 reference

Europe PubMed Central

16 September 2017

5

1 reference

Europe PubMed Central

16 September 2017

Cancer and the microenvironment: myeloma-osteoclast interactions as a model

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2007.10.021

7 January 2021

New potential targets for treating myeloma bone disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2007.10.021

7 January 2021

Osteoclast differentiation and activation

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2007.10.021

7 January 2021

Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2007.10.021

7 January 2021

RANK ligand and osteoprotegerin in myeloma bone disease.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2007.10.021

7 January 2021

Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2007.10.021

7 January 2021

Degradation of collagen in the bone-resorbing compartment underlying the osteoclast involves both cysteine-proteinases and matrix metalloproteinases

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2007.10.021

7 January 2021

Matrix metalloproteinases (MMP) and cathepsin K contribute differently to osteoclastic activities

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2007.10.021

7 January 2021

The collagenolytic activity of cathepsin K is unique among mammalian proteinases

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2007.10.021

7 January 2021

The role of the plasminogen system in bone resorption in vitro

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2007.10.021

7 January 2021

The effects of serine proteinase inhibitors on bone resorption in vitro

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2007.10.021

7 January 2021

Novel targeted drugs for the treatment of multiple myeloma: from bench to bedside

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2007.10.021

7 January 2021

Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2007.10.021

7 January 2021

Bortezomib inhibits human osteoclastogenesis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2007.10.021

7 January 2021

Hepatocyte growth factor/c-Met signaling promotes the progression of experimental human neuroblastomas

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2007.10.021

7 January 2021

Human primary osteoclasts: in vitro generation and applications as pharmacological and clinical assay

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2007.10.021

7 January 2021

Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple Myeloma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2007.10.021

7 January 2021

Combined disruption of both the MEK/ERK and the IL-6R/STAT3 pathways is required to induce apoptosis of multiple myeloma cells in the presence of bone marrow stromal cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2007.10.021

7 January 2021

Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2007.10.021

7 January 2021

Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2007.10.021

7 January 2021

CXCL12 chemokine up-regulates bone resorption and MMP-9 release by human osteoclasts: CXCL12 levels are increased in synovial and bone tissue of rheumatoid arthritis patients.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2007.10.021

7 January 2021

Increased bone formation in mice lacking plasminogen activators.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2007.10.021

7 January 2021

Matrix metalloproteinases in skin

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2007.10.021

7 January 2021

Osteoclastic bone degradation and the role of different cysteine proteinases and matrix metalloproteinases: differences between calvaria and long bone

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2007.10.021

7 January 2021

MMP-9 antisense oligodeoxynucleotide exerts an inhibitory effect on osteoclastic bone resorption by suppressing cell migration.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2007.10.021

7 January 2021

Relationship of the plasminogen activator/plasmin cascade to osteoclast invasion and mineral resorption in explanted fetal metatarsal bones

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2007.10.021

7 January 2021

Proteinases in bone resorption: obvious and less obvious roles.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2007.10.021

7 January 2021

Interactions between insulin-like growth factor-I (IGF-I) and the system of plasminogen activators and their inhibitors in the control of IGF-binding protein-3 production and proteolysis in human osteosarcoma cells.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2007.10.021

7 January 2021

Multifunctional role of matrix metalloproteinases in multiple myeloma: a study in the 5T2MM mouse model

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2007.10.021

7 January 2021

Regulation of matrix metalloproteinase expression in tumor invasion.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2007.10.021

7 January 2021

Normalizing the bone marrow microenvironment with p38 inhibitor reduces multiple myeloma cell proliferation and adhesion and suppresses osteoclast formation.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2007.10.021

7 January 2021

Expression of membrane type 1 matrix metalloproteinase in papillomavirus-positive cells: role of the human papillomavirus (HPV) 16 and HPV8 E7 gene products

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2007.10.021

7 January 2021

Signal transducer and activator of transcription 3 activation promotes invasive growth of colon carcinomas through matrix metalloproteinase induction

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2007.10.021

7 January 2021

Identifiers

10.1016/J.YEXCR.2007.10.021

1 reference

Europe PubMed Central

16 September 2017

1 reference

Europe PubMed Central

16 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40041623&oldid=1517909320"